Passes v. Micromet/Amgen

CONCLUDED

Hearing
02/27/12 – 02/27/12

Play button overlay 45f08f27c7337d189e8c31e635b5d0a0781b273131135cd77ee8b6f12366e7a2
Play button overlay 45f08f27c7337d189e8c31e635b5d0a0781b273131135cd77ee8b6f12366e7a2

Summary

In this pharmaceutical Mergers and acquisition hearing, Plaintiff shareholder Bernard Passes alleged Micromet Inc. of failing in its duty to get the best price for its shareholder by agreeing to Amgen Inc’s offer of acquiring the company at $11 a share. The plaintiff’s counsels argued to block the proposed deal between Micromet Inc. and Amgen Inc. in which Amgen was acquiring Micromet in order to gain control over the experimental Lukemia drug. The plaintiff’s counsels claimed that given Micromet’s growth prospect and potential future earnings, the price of $11 per share was too low.

The plaintiff was represented by attorney Jason Leviton. The defense in this case comprised of Amgen Inc and Micromet Inc. Amgen Inc. was represented by attorney Robert Sacks. Micromet Inc. was represented by attorney Koji Fukumura.

Recording Disclaimer: This proceeding was recorded in full.

Suggest a Trial

Want to see a trial that you don't see in our list of upcoming trials?

Suggest a Case

CVN Essentials

The most important and informative moments of each trial

CVN Essentials

Video Library

Unlimited access to thousands of hours of past coverage of high stakes civil litigation

Video Library

  • Follow Us
  • Contact Us
  • 3901 Roswell Road
  • Suite 302
  • Marietta, GA 30062
  • 877-838-9067

Copyright 2018 Courtroom Connect.